Mycophenolate Mofetil Hexal (Mycophenolate Mofetil)

The drug inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for the synthesis of guanosine nucleotides in lymphocytes. By limiting these nucleotides, Mycophenolate Mofetil reduces the proliferation of T‑ and B‑cells, thereby dampening the immune response that can cause organ rejection or autoimmune damage.

The dosage of Mycophenolate Mofetil Hexal is individualized and set by the prescribing clinician based on the patient’s condition, weight, renal function, and other factors. Patients should follow the exact dosing instructions provided by their healthcare professional and not adjust the dose on their own.

The safety of Mycophenolate Mofetil in pregnancy and lactation is not well established, and it is generally classified as contraindicated for use in pregnant women due to potential fetal harm. Women of child‑bearing potential should use effective contraception, and breastfeeding decisions should be made in consultation with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with calcineurin inhibitors such as cyclosporine or tacrolimus, Mycophenolate Mofetil offers a different mechanism—targeting nucleotide synthesis rather than calcineurin signaling. It is often used in combination regimens to provide synergistic immunosuppression while potentially reducing the dose‑related toxicities of each individual agent.

Mycophenolate Mofetil Hexal tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposing it to excessive heat or humidity.

The medication is taken orally, usually with food or a glass of water to reduce gastrointestinal discomfort. The exact schedule—once or twice daily—depends on the prescribing clinician’s plan and the specific clinical indication.

Serious risks include bone‑marrow suppression leading to leukopenia or anemia, severe infections such as opportunistic fungal or viral illnesses, liver toxicity, and an increased long‑term risk of certain malignancies, particularly post‑transplant lymphoproliferative disorders.

Patients with known hypersensitivity to Mycophenolate Mofetil or any component of the formulation should avoid the drug. It is also contraindicated in individuals receiving live vaccines, those with uncontrolled infections, and pregnant women unless the potential benefits outweigh the risks.